CJC-1295 with DAC: Tracking the Long-Acting GHRH Analog

CJC-1295 with DAC is a modified GHRH analog. The Drug Affinity Complex (DAC) binds the peptide to circulating albumin, extending the half-life from minutes to roughly 6-8 days. That long tail is the entire point of the DAC version, and it's also why tracking looks different from the no-DAC form.

What it does

CJC-1295 binds the GHRH receptor on the pituitary and increases GH release. With DAC attached, plasma levels stay elevated for days, producing a sustained "bleed" of GH rather than discrete pulses. Human data is limited to a small set of phase 1 and 2 trials from the original developer; longer-term safety in healthy adults has not been characterized.

Typical protocol shape

• Frequency: once or twice weekly is the most commonly reported pattern
• Dose: trial doses ranged from ~30 to 250 mcg/kg; self-experimenter reports cluster much lower, often 1-2 mg per week split into two injections
• Duration: cycles of 8-12 weeks with a break are common in user reports, though no formal protocol exists

Why DAC changes the tracking picture

With no-DAC GHRH, GH pulses follow the injection by 15-30 minutes and resolve quickly. With DAC, GH is elevated continuously, which means:

• IGF-1 becomes the primary biomarker, not GH itself
• Acute side effects (water retention, tingling, drowsiness) build over days rather than hitting fast
• Stopping doesn't immediately clear the signal — taper effects can persist a week

What to track daily

• Injection site, dose, time
• Fasting morning energy (1-10)
• Sleep quality and total sleep time
• Hand/ankle puffiness or ring tightness
• Numbness or tingling in fingers
• Appetite changes

What to track weekly

• Morning weight (same scale, same time)
• Waist circumference
• Resting heart rate trend
• Recovery quality after training
• Any joint pain or carpal tunnel symptoms

Bloodwork worth doing

• Baseline before starting: IGF-1, fasting glucose, HbA1c, fasting insulin, CBC, CMP
• IGF-1 at week 4 and week 8 — this is the lever you actually have
• Fasting glucose and HbA1c at week 8 — GH elevation can nudge insulin resistance

A reasonable IGF-1 target stays within the upper third of the age-adjusted reference range. Pushing well above the range is where risk-benefit gets unclear.

Realistic expectations

Sleep depth and skin quality changes are the most commonly reported early effects. Body composition shifts are slow and modest in users who track honestly with photos and DEXA. People expecting fast fat loss or visible muscle gain in 4 weeks are usually disappointed.

Common mistakes

• Stacking with a GHRP (like ipamorelin) on a daily schedule, defeating the convenience of a long-acting compound
• Chasing higher doses when IGF-1 is already mid-range
• Ignoring fasting glucose drift
• Not pausing long enough between cycles to see a true off-cycle baseline

CJC-1295 DAC vs no-DAC at a glance

• DAC: weekly dosing, sustained GH elevation, IGF-1 driven tracking
• No-DAC (Mod GRF 1-29): multiple daily injections, pulsatile pattern, closer to natural physiology

The two are different tools. DAC trades pulse fidelity for convenience.

A tracking template

In Peptide IA, a useful schema for DAC is: injection log with day-of-week tags, daily wellness sliders for sleep and puffiness, weekly weight and waist, and a bloodwork log with IGF-1 plotted against dose changes over time.

Bottom line

CJC-1295 with DAC is the convenient-but-blunt instrument in the GHRH family. Track IGF-1, not vibes, and respect that you're holding the receptor on for days at a time.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.